ATS Corporation to Participate in Jefferies Industrials Conference and Provides NCIB Update
ATS Corporation (TSX and NYSE: ATS), a global automation and technology company, has announced that senior members of its leadership team will participate in the Jefferies Industrials Conference in New York City on September 10, 2026. Anne Cybulski, Interim Chief Financial Officer, and Sarah Moore, Group Executive, Life Sciences, will represent the company at the conference, where they are scheduled to engage with investors and discuss ATS’s business strategy, operating priorities and growth opportunities.
As part of its participation, ATS will host a fireside chat at 12:10 p.m. Eastern Time. The session is expected to provide investors and other market participants with an opportunity to hear directly from company leadership about ATS’s performance, strategic priorities and outlook across its diverse automation and life sciences businesses.
The live webcast of the event will be made available through ATS’s Investor Relations website in the Events & Presentations section. Investors who are unable to attend the session in real time will also have access to a replay, which will remain available on the company’s Investor Relations website for 180 days.
In addition to the fireside chat, ATS management will conduct meetings with institutional investors during the conference. These meetings are intended to provide investors with additional opportunities to discuss the company’s business and strategic direction directly with its leadership team. Institutional investors interested in arranging meetings can do so through their Jefferies representative or by contacting ATS’s investor relations team.
Investor Engagement and Strategic Priorities
Participation in industry and investment conferences provides ATS with an important platform for communicating with shareholders and the broader financial community. The Jefferies Industrials Conference brings together companies and institutional investors, creating an environment for detailed discussions about market conditions, business performance and future opportunities.
For ATS, the involvement of both its finance leadership and Life Sciences leadership reflects the breadth of the company’s operations. Cybulski brings a financial and capital allocation perspective to the discussion, while Moore provides insight into the company’s Life Sciences business and its role within ATS’s overall portfolio.
The fireside chat may also offer investors an opportunity to better understand how ATS is navigating changing market conditions while maintaining its focus on sustainable growth. As a company focused on automation and technology, ATS operates in markets where manufacturers and other customers increasingly seek advanced solutions to improve productivity, efficiency, quality and operational performance.
Update on Normal Course Issuer Bid
Alongside the conference announcement, ATS provided an update on purchases of its common shares under its previously disclosed normal course issuer bid, or NCIB.
The company stated that it believes there are periods when the market price of its common shares may not fully reflect their underlying value. In such circumstances, ATS believes that repurchasing shares can provide liquidity to existing shareholders while potentially benefiting shareholders who continue to hold their shares.
Through August 2026, ATS had purchased 1,119,413 common shares at an average price of $27.97 per share. This total includes the 146,085 shares that the company had previously disclosed.
Share repurchases are an important component of ATS’s broader capital allocation strategy. By purchasing shares for cancellation when management believes they are attractively valued, the company can deploy capital while potentially reducing the number of shares outstanding.
The NCIB therefore provides ATS with flexibility to return capital to shareholders while maintaining the ability to invest in other areas of the business.
NCIB Authorization Through December 2026
Under the company’s NCIB, ATS has the ability to purchase for cancellation up to a maximum of 8,225,621 common shares.
The current NCIB became effective on December 22, 2025, and will continue for a twelve-month period ending on or before December 21, 2026, subject to applicable regulatory requirements.
ATS may conduct purchases through the facilities of the Toronto Stock Exchange and/or alternative Canadian trading systems. The company may also execute purchases through block transactions and its automatic purchase plan, subject to the applicable rules and regulations governing the NCIB.
The price paid for shares acquired under the program will be the prevailing market price at the time of acquisition.
ATS has indicated that it expects to remain active under the NCIB. The company’s continued participation in the program demonstrates management’s view that share repurchases can be complementary to its broader strategic objectives.
Capital Allocation and Acquisition Growth
ATS views the NCIB as one component of its overall capital allocation strategy rather than an isolated financial initiative. The company’s approach combines share repurchases with investments intended to support long-term business growth.
In particular, ATS views the NCIB as complementary to its acquisition growth plans. Acquisitions have been an important component of the company’s strategy, allowing ATS to expand its technology capabilities, strengthen its market position and broaden its customer relationships.
Balancing acquisitions with share repurchases gives ATS flexibility in determining how best to deploy available capital. When attractive acquisition opportunities arise, the company can direct resources toward expanding its operations and capabilities. When management believes the company’s shares are undervalued, repurchasing common shares can provide another avenue for capital deployment.
This balanced approach allows ATS to pursue both organic and inorganic growth while maintaining a focus on shareholder value.
Automation and Life Sciences Opportunities
ATS operates in technology-driven markets where automation continues to play an increasingly important role. Manufacturers across industries are looking for ways to improve production efficiency, address workforce challenges, increase precision and enhance product quality.
Automation technologies can help companies modernize production environments and respond to evolving customer requirements. ATS’s capabilities position it to participate in these trends by providing automated manufacturing solutions and technologies designed for complex production requirements.
The Life Sciences business is another important component of ATS’s portfolio. Companies operating in life sciences and related industries often require highly precise, reliable and scalable manufacturing processes. Automation can play a critical role in helping these customers improve production performance while maintaining stringent quality standards.
Sarah Moore’s participation at the Jefferies conference is expected to provide investors with additional perspective on the Life Sciences segment and its contribution to ATS’s overall strategy.
Focus on Long-Term Shareholder Value
ATS’s announcement combines two important aspects of its corporate strategy: investor engagement and capital allocation.
The company’s participation in the Jefferies Industrials Conference will provide management with an opportunity to communicate directly with institutional investors, while the NCIB update demonstrates how ATS is actively deploying capital within the framework of its broader strategic objectives.
The company’s belief that its common shares may at times trade below their underlying value is a key consideration behind its share repurchase activity. By purchasing shares at market prices, ATS seeks to provide liquidity while potentially increasing the relative ownership interest of remaining shareholders.
At the same time, the company remains focused on acquisition-driven growth. The combination of acquisitions and share repurchases reflects an effort to balance near-term capital deployment with investments that can support long-term expansion.
Looking Ahead
The September 10 appearance at the Jefferies Industrials Conference will give investors an opportunity to hear from ATS leadership as the company continues to execute its growth and capital allocation strategies.
Anne Cybulski and Sarah Moore are scheduled to participate in the 12:10 p.m. ET fireside chat, with the live webcast available through ATS’s Investor Relations website. A replay will remain accessible for 180 days following the event.
Meanwhile, ATS expects to remain active under its NCIB through the remainder of the current authorization period. With the ability to purchase up to 8,225,621 common shares for cancellation, the company retains considerable flexibility to continue its repurchase activity, subject to market conditions and applicable regulatory requirements.
By combining investment in its businesses, acquisition opportunities and share repurchases, ATS is pursuing a capital allocation strategy designed to support sustainable growth and shareholder value. Its continued focus on automation and Life Sciences markets also positions the company to benefit from the increasing adoption of advanced manufacturing technologies.
The company’s upcoming investor discussions in New York will therefore provide an important opportunity to communicate its strategic priorities, financial approach and outlook while reinforcing its commitment to disciplined execution and long-term value creation.
Source link:https://www.businesswire.com/
